Strategic Growth Target mid-market wellness brands and clinics seeking osteoarthritis and joint health solutions; ZyCal’s Ostinol line offers a differentiated, clinically supported cellular nutrition approach that can complement existing bone and joint product portfolios.

Clinical Differentiator Leverage Cyplexinol Pro as a unique selling point to partnerships with nutraceutical distributors, orthopedic clinics, and sports medicine centers looking for evidence-based bone and cartilage support therapies.

Manufacturing Advantage Promote the FDA registered, non-GMO production facility and adherence to GMP as a quality assurance differentiator when engaging potential contract manufacturers, co-packers, or private-label opportunities.

Channel Expansion Explore collaborations with wellness retailers and e-commerce platforms targeting aging populations and active adults; emphasize Ostinol’s long clinical track record and consumer direct availability.

Financial & Scale Fit Position ZyCal as a lean, employee-owned partner with a revenue range that aligns with growing regional distributors and specialty retailers seeking proven, scalable bone and joint products with strong clinical backing.